Home > Newsletters > Drug Industry Daily > Endo Petitions FDA to Maintain Opana Control as More Generic Companies Submit ANDAs
Drug Industry Daily
Oct. 1, 2012 | Vol. 11 No. 192
Endo Petitions FDA to Maintain Opana Control as More Generic Companies Submit ANDAs
Endo Pharmaceuticals is petitioning the FDA to require generics referencing its crush-resistant pain drug, Opana ER CRF, demonstrate they are similarly crush-resistant.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.